Markets Stocks Economy Crypto Earnings Banking Energy
Home› Stocks› Feature
Breaking · Stocks

Gedeon Richter to buy Mayne Pharma for A$604 million

Gedeon Richter to buy Mayne Pharma for A$604 million
Stocks · 2026
Photo · Marcus Devlin for Daily Digest Invest
By Marcus Devlin Equities Correspondent Nov 17, 2026 4 min read

Hungarian drugmaker Gedeon Richter has agreed to acquire Australian pharmaceutical company Mayne Pharma in a deal valued at about A$604 million (roughly US$400 million). Under the terms, Richter will pay A$6.40 per share in cash, a 99.4% premium to Mayne's closing price on the day before the announcement. The offer has the backing of Mayne's board, though it remains subject to several conditions, including regulatory approvals and an independent expert's fairness opinion.

Mayne Pharma, based in Adelaide, develops and sells both branded and generic medicines. Its portfolio spans dermatology, women's health, and other therapeutic areas. The company also has a significant presence in the U.S. market, where it markets a range of generic products. On the news, Mayne's shares jumped 86% before settling around A$5.97, reflecting the market's initial reaction to the offer.

Why Richter is buying

For Gedeon Richter, the acquisition is primarily about expanding its women's health franchise. Mayne's portfolio includes an estetrol-based contraceptive, a product that Richter believes has strong growth potential. Estetrol is a naturally occurring estrogen used in newer combined oral contraceptives, and Richter sees it as a key asset to drive future revenue.

Beyond the product itself, Richter is attracted to Mayne's U.S. sales network. The company's management has said that this distribution infrastructure will help Richter reach more patients and strengthen its commercial footprint in the world's largest pharmaceutical market. This is part of a broader trend where mid-sized European drugmakers look to acquire U.S. distribution capabilities to grow without building from scratch.

The deal also comes at a time when the pharmaceutical industry is seeing increased M&A activity, as companies seek to bolster pipelines and market access. For Richter, which has traditionally focused on Central and Eastern Europe, this acquisition marks a significant step into the U.S. market.

Conditions and risks

The transaction is not a simple cash-and-done deal. It is conditional on several factors. First, Mayne must complete the sale of its International business segment to Evaris Pharma, a separate transaction that has been agreed but not yet closed. This divestment is a prerequisite for the Richter deal to proceed.

Second, the offer requires approval from Australian regulators, including the Foreign Investment Review Board (FIRB), which scrutinises foreign acquisitions for national interest concerns. Given the relatively small size of the deal and the non-sensitive nature of the business, approval is likely but not guaranteed.

Third, Mayne's board has said it will recommend the offer to shareholders, but only if no superior proposal emerges and an independent expert concludes that the deal is fair and reasonable. This is a standard safeguard in Australian takeovers, designed to protect minority shareholders.

If any of these conditions fail, the deal could collapse, leaving Mayne's shares to fall back to pre-announcement levels. That risk is why the stock is trading below the offer price.

What it means for investors

For investors holding Mayne shares, the gap between the current price (around A$5.97) and the offer price (A$6.40) is a real-time indicator of "deal risk." In a cash takeover, the target's stock typically trades at a discount to the offer price because investors demand compensation for the time it takes to close and the possibility that the deal falls through.

In this case, the roughly A$0.43 spread (about 7%) reflects the market's assessment of the likelihood that all conditions will be met. If the spread narrows, it suggests investors are becoming more confident that the deal will complete. If it widens, it signals growing doubts about regulatory approval, the Evaris sale, or the independent expert's verdict.

For Gedeon Richter shareholders, the deal represents a strategic bet on the U.S. women's health market. The company is paying a substantial premium, which could weigh on its near-term earnings if the acquisition underperforms. However, if the estetrol-based contraceptive gains traction, the long-term payoff could be significant.

For the broader market, this deal is another example of cross-border pharmaceutical M&A, a trend that has been active in recent years. Investors in the sector should watch for similar moves, as companies seek growth through acquisitions rather than organic R&D alone. For more on how M&A activity is shaping the sector, see our coverage of LEO Pharma's IPO delays and Flagship's AI biotech investments.

As always, investors should consider the risks. Takeover deals can be long and uncertain. The independent expert's report, which will be released to shareholders, will provide more detail on the fairness of the offer. Until then, the share price will continue to reflect the market's collective view on the odds of completion.

More from this story

Next article · Don't miss

TSX slides to six-week low as AI jitters hit tech shares

Canada's main stock index dropped to its lowest close in nearly six weeks, dragged down by tech and industrial shares as investors grew nervous ahead of Nvidia's earnings. Materials edged higher after Panama agreed to reopen talks on First Quantum's Cobre Pana

Read the story →
TSX slides to six-week low as AI jitters hit tech shares